Ravi Shankar – Page 59

Stifel Reports Third Quarter 2026 Results

Posted on October 21, 2026 by Ravi Shankar

ST. LOUIS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.43 billion for the three months ended September 30, 2026, compared with $1.43 billion a year ago. Net income available to common shareholders was $224.8 million, or $1.40 per diluted common share, compared with $202.1 million, or $1.22 per diluted common share ⁽¹⁾ for the third quarter of 2025. Non-GAAP net income available to common shareholders was $234.1 million, or $1.46 per diluted common share for the third quarter of 2026.

Ronald J. Kruszewski, Chairman and Chief Executive Officer, said “Stifel is on track for another record year, with year-to-date revenue of $4.3 billion up 9%, core earnings per share of $4.33 up 22%, and return on tangible common equity of 24.1%. The investments we’ve made in our business continued to drive operating efficiencies, as we delivered our highest ever third quarter earnings per share of $1.46, up 12% versus the prior year, on net revenue of $1.43 billion. I am optimistic about our outlook, as Stifel’s diversified business model, recurring revenue stream, and disciplined capital management position us to keep compounding value for shareholders.”

Highlights

The Company reported net revenues of $1.43 billion, the second best third quarter in its history, driven by higher asset management revenues and net interest income.
Non-GAAP net income available to common shareholders of $1.46 per diluted common share, the best third quarter in its history.
Asset management revenues increased 14% over the year-ago quarter.
Net interest income increased 9% over the year ago quarter.
Bank loans increased 21% over the year ago quarter.
Client assets of $576.5 billion, up 6% over the year-ago quarter.
Over the last twelve months, recruited trailing twelve-month production totaled approximately $19 million.
Non-GAAP pre-tax margin of 22.5%.
Annualized return on tangible common equity (ROTCE) ⁽⁶⁾ of 23.9%.
Tangible book value per common share ⁽⁹⁾of $26.05, up 12% from prior year.
The Company repurchased $124.0 million, or 1.6 million shares, of its outstanding common stock during the third quarter at an average price of $76.95.
Announced strategic investment in Meow Technologies.

Financial Summary (Unaudited)
(000s)	3Q 2026		3Q 2025		9m 2026		9m 2025
GAAP Financial Highlights:
Net revenues	$1,426,211		$1,429,396		$4,355,176		$3,969,151
Net income⁽²⁾	$224,823		$202,051		$684,078		$391,457
Diluted EPS^{(1) (2)}	$1.40		$1.22		$4.23		$2.37
Comp. ratio		57.0%		58.8%		57.3%		59.1%
Non-comp. ratio		21.3%		21.2%		21.2%		26.7%
Pre-tax margin		21.7%		20.0%		21.5%		14.2%
Non-GAAP Financial Highlights:
Net revenues	$1,429,077		$1,429,398		$4,323,903		$3,969,231
Net income⁽²⁾⁽³⁾	$234,096		$214,419		$700,872		$454,281
Diluted EPS^{(1) (2) (3)}	$1.46		$1.30		$4.33		$2.76
Comp. ratio⁽³⁾		56.6%		58.0%		57.0%		58.0%
Non-comp. ratio⁽³⁾		20.9%		20.8%		20.9%		25.9%
Pre-tax margin⁽⁴⁾		22.5%		21.2%		22.1%		16.1%
ROCE⁽⁵⁾		17.4%		17.0%		17.5%		12.2%
ROTCE⁽⁶⁾		23.9%		24.3%		24.1%		17.3%
*Global Wealth Management (assets and loans in millions***)
Net revenues	$980,293		$907,440		$2,868,950		$2,603,630
Pre-tax net income	$374,408		$342,650		$1,066,970		$775,111
Total client assets⁽⁷⁾	$576,482		$544,010
Fee-based client assets⁽⁷⁾	$239,661		$219,178
Bank loans⁽⁸⁾	$26,065		$21,635
Institutional Group

Net revenues	$430,281	$500,435	$1,406,233	$1,305,143
Equity	$282,574	$296,677	$915,506	$753,037
Fixed Income	$147,707	$203,758	$490,727	$552,106
Pre-tax net income	$76,261	$89,291	$266,348	$177,762

Global Wealth Management

Global Wealth Management reported record net revenues of $980.3 million for the three months ended September 30, 2026, compared with $907.4 million during the third quarter of 2025. Pre-tax net income was $374.4 million compared with $342.7 million in the third quarter of 2025.

Highlights

Client assets of $576.5 billion, up 6% over the year-ago quarter, which included $10.2 billion of client assets from the Stifel Independent Advisors business that was sold on February 2, 2026.
Fee-based client assets of $239.7 billion, up 9% over the year-ago quarter, which included $4.8 billion of client assets from the Stifel Independent Advisors business that was sold on February 2, 2026.
Over the last twelve months, recruited trailing twelve-month production totaled approximately $19 million.

Net revenues increased 8% from a year ago:

Transactional revenues decreased 3% over the year-ago quarter, reflecting a decrease in client activity.
Asset management revenues increased 14% over the year-ago quarter, reflecting higher asset values due to improved market conditions and net new asset growth.
Net interest income increased 11% over the year-ago quarter primarily driven by balance sheet growth, partially offset by lower interest rates.

Total Expenses:

Compensation expense as a percentage of net revenues increased modestly to 48.8% primarily driven by higher revenue-related compensation, partially offset by revenue growth.
Provision for credit losses decreased from a year ago primarily as a result of a modest improvement in macroeconomic conditions, partially offset by loan growth in the retained portfolio and specific reserves on individual credits.
Non-compensation operating expenses as a percentage of net revenues decreased to 13.0% primarily attributable to lower litigation-related expenses, a decrease in the provision for credit losses, and revenue growth over the year-ago quarter.

Summary Results of Operations

(000s)		3Q 2026		3Q 2025
Net revenues	$980,293		$907,440
Transactional revenues		196,213		203,078
Asset management		492,123		431,363
Net interest income		284,583		257,327
Investment banking		6,731		6,529
Other income		643		9,143

Total expenses	$605,885		$564,790
Compensation expense		478,877		441,626
Provision for credit losses		7,926		8,316
Non-comp. operating expenses		119,082		114,848
Pre-tax net income	$374,408		$342,650
Compensation ratio		48.8%		48.7%
Non-compensation ratio		13.0%		13.5%
Pre-tax margin		38.2%		37.8%

Institutional Group

Institutional Group reported net revenues of $430.3 million for the three months ended September 30, 2026, compared with $500.4 million during the third quarter of 2025. Pre-tax net income was $76.3 million compared with $89.3 million in the third quarter of 2025.

Highlights

Investment banking revenues decreased 6% from a year ago:

Advisory revenues decreased 4% from the year-ago quarter, driven by lower levels of completed advisory transactions.
Equity capital raising revenues decreased 13% from the year-ago quarter, driven by lower volumes and smaller deal sizes.
Fixed income capital raising revenues decreased 2% over the year-ago quarter primarily driven by lower bond issuances.

Fixed income transactional revenues decreased 34% from a year ago:

Fixed income transactional revenues were impacted by widening credit spreads, increased market volatility, and lower realized trading gains during the quarter.

Equity transactional revenues decreased 29% from a year ago:

Equity transactional revenues were impacted by lower realized trading gains, a decline in trading volumes over the year-ago quarter and the restructuring of our European Equities business, which resulted in a $7 million reduction in equity transactional revenues year over year.

Total Expenses:

Compensation expense as a percentage of net revenues decreased to 58.7% primarily attributable to lower revenue-related compensation due to a decline in revenues from the year ago quarter.
Non-compensation operating expenses as a percentage of net revenues increased to 23.6% primarily attributable to a decline in revenues from the year ago quarter.

Summary Results of Operations
Summary Results of Operations
(000s)		3Q 2026		3Q2025
Net revenues	$430,281		$500,435
Investment banking		299,472		316,954
Advisory		173,017		179,270
Equity capital raising		68,556		78,765
Fixed income capital raising		57,899		58,919
Fixed income transactional		80,472		122,567
Equity transactional		41,195		58,306
Other		9,142		2,608
Total expenses	$354,020		$411,144
Compensation expense		252,656		297,106
Non-comp. operating expenses		101,364		114,038
Pre-tax net income	$76,261		$89,291
Compensation ratio		58.7%		59.4%
Non-compensation ratio		23.6%		22.8%
Pre-tax margin		17.7%		17.8%

Other Matters

Highlights

Total assets increased $3.6 billion, or 9%, from the year-ago quarter.
Over the last twelve months, the Company repurchased $564.4 million, or 7.3 million shares, of its outstanding common stock at an average price of $77.05.
Weighted average diluted shares outstanding decreased primarily due to share repurchases.
The Board of Directors declared a $0.34 quarterly dividend per share, payable on September 15, 2026, to common shareholders of record on September 1, 2026.
The Board of Directors declared a quarterly dividend on the outstanding shares of the Company’s preferred stock, payable on September 15, 2026, to shareholders of record on September 1, 2026.

	3Q 2026		3Q 2025
Common stock repurchases⁽¹⁾
Repurchases (000s)	$124,005		$33,086
Number of shares (000s)		1,612		438
Average price	$76.95		$75.57
Period end shares (000s)		150,061		152,922
Weighted average diluted shares outstanding (000s)		160,145		165,087
Effective tax rate		24.4%		26.1%
Stifel Financial Corp.⁽¹⁰⁾
Tier 1 common capital ratio	`14.5%			14.8%
Tier 1 risk-based capital ratio		17.0%		17.6%
Tier 1 leverage capital ratio		10.8%		11.1%
Tier 1 capital (MM)	$4,665		$4,267
Risk weighted assets (MM)	$27,450		$24,235
Average assets (MM)	$43,060		$38,332
Quarter end assets (MM)	$45,282		$41,687
Agency	Rating		Outlook
Fitch Ratings	BBB+		Stable
S&P Global Ratings	BBB		Stable

Conference Call Information

Stifel Financial Corp. will host its third quarter 2026 financial results conference call on Wednesday, October 21, 2026, at 9:30 a.m. Eastern Time. The conference call may include forward-looking statements.

All interested parties are invited to listen to Stifel’s Chairman and CEO, Ronald J. Kruszewski, by dialing (800) 330-6710 and referencing conference ID 9806728. A live audio webcast of the call, as well as a presentation highlighting the Company’s results, will be available through the Company’s web site, www.stifel.com. For those who cannot listen to the live broadcast, a replay of the broadcast will be available through the above-referenced web site beginning approximately one hour following the completion of the call.

Labrador Gold Announces Extension of Non-Brokered Private Placement

Posted on October 21, 2026 by Ravi Shankar

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) announces that further to its press releases dated September 17, 2026, October 13, 2026, and October 20, 2026 it has extended its non-brokered private placement offering for up to a further thirty (30) days.

The non-brokered private placement offering consists of: (i) common shares of the Company issued on a non-flow-through basis (the “HD Shares”); and (ii) common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) (the “FT Shares” and, together with the HD Shares, the “Shares”), each at a price of $0.05 per Share, for aggregate gross proceeds of a minimum of $2,000,000 and a maximum of $7,000,000, representing the issuance of between 40,000,000 and 140,000,000 Shares (the “Offering”).

The Company closed on the first tranche with subscriptions by Matachewan Consolidated Mines, Limited (TSX.V: MCM-A) (“Matachewan”) and McChip Resources Inc. (TSX.V: MCS) (“McChip” and, together with Matachewan, the “Lead Investors”) for $2,133,790.45 of FT Shares, representing 42,675,809 FT Shares. See the Company’s press release from October 20, 2026 for additional details in relation to the Closing of the first tranche.

The Offering will remain open until the earlier of the sale of the remaining HD Shares and FT Shares and November 6, 2026.

The Offering

The Offering consists of the Shares, each at a price of $0.05 per Share, for aggregate gross proceeds of a maximum of $7,000,000, representing the issuance of up to 140,000,000 Shares.

The Offering will close a second tranche on or about October 23, 2026, with a final closing on or before November 6, 2026. The participants in, and the number of HD Shares and FT Shares to be issued under any further tranches will be determined by the Company and the Lead Investors, provided that the aggregate gross proceeds of the Offering will not exceed $7,000,000. Prior to the final closing of the Offering, the Lead Investors intend to subscribe for HD Shares such that, together with the FT Shares acquired in the first tranche, the Lead Investors will collectively hold up to 19.99% of the issued and outstanding common shares of the Company following completion of the Offering.

The gross proceeds from the sale of the FT Shares will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures”, as those terms are defined in the Tax Act (the “Qualifying Expenditures”), on the Company’s mineral properties in Canada. The Company will renounce the Qualifying Expenditures in favour of the subscribers of the FT Shares with an effective date no later than the date permitted under the Tax Act, in an aggregate amount not less than the gross proceeds raised from the issuance of the FT Shares. The net proceeds from the sale of the HD Shares will be used for exploration and development activities, working capital and general corporate purposes.

All securities issued under the Offering will be subject to a hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws and the policies of the TSX Venture Exchange (the “TSXV”). The Offering remains subject to final acceptance of the TSXV. The Company does not intend to pay finder’s fees in connection with the Offering.

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable securities laws of any state of the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction.

Four insiders of the Company intend to subscribe for 8,700,000 FT Shares and 3,000,000 HD Shares for an aggregate of $585,000 on the closing of the second tranche. The insider private placements are exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (“MI 61-101”) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company which will be issued to the insiders will not exceed 25% of its market capitalization.

About Labrador Gold

Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.

The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects.

The Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.

The Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.

The Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.

The Company has 213,485,788 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.

For more information, please contact:

Roger Moss, President and CEO

Tel: 416-704-8291

Website: www.labradorgold.com

X: @LabGoldCorp

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding the completion, size, pricing, structure and timing of the Offering, including the closing of any further tranches; the number and composition of Shares to be issued under the Offering; the participation of the Lead Investors, insiders and other subscribers; the anticipated use of the proceeds of the Offering; the Company’s intention to incur and renounce Qualifying Expenditures; and the receipt of corporate and TSXV approvals.

Forward-looking statements are based on management’s current expectations, estimates, assumptions and beliefs as of the date of this release, including assumptions regarding the satisfaction of the conditions to closing; the availability of applicable prospectus exemptions; the receipt of all required corporate and regulatory approvals, including the acceptance of the TSXV; the availability of sufficient subscriber demand; the ability of subscribers to fund their subscriptions; the absence of a material adverse change before closing; the availability of Qualifying Expenditures; and the Company’s ability to incur and renounce the Qualifying Expenditures within the periods required under the Tax Act.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Offering may be delayed, reduced, restructured or not completed on the terms described or at all; that the Company may raise less than the maximum amount contemplated; that subscribers may withdraw or fail to fund their subscriptions; that required corporate or regulatory approvals, including TSXV acceptance, may not be obtained; that sufficient Qualifying Expenditures may not be available; that the Company may not incur or renounce Qualifying Expenditures within the periods required under the Tax Act; and the risks described in the Company’s continuous disclosure filings with Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Posted in UncategorizedTagged GlobeNewswire

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Posted on October 21, 2026 by Ravi Shankar

BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update.

To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

Roivant will also host an investor day on Wednesday, December 9, 2026. To attend the event in person or by webcast, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

About Roivant
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, the timing of potential regulatory approvals for our product and product candidates, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com

Media
Stephanie Lee
stephanie.lee@roivant.com

Posted in UncategorizedTagged GlobeNewswire

West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers

Posted on October 21, 2026 by Ravi Shankar

BrewDog Boleyn

ELLON, Scotland and LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) — BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), and West Ham United Football Club today unveiled Boleyn Brew, a first-of-its-kind fan-created beer built with West Ham supporters and brewed for matchday. From flavour and style to storytelling, branding and name, Hammers helped shape every part of the beer. Boleyn Brew makes its debut at London Stadium this Saturday when West Ham United take on Southampton, with limited-edition cans available to buy online from today.

Created by Hammers, for Hammers, Boleyn Brew brings together BrewDog’s brewing expertise with the pride, loyalty and unmistakable character of the Claret and Blue faithful. As West Ham United’s Official Beer Partner, BrewDog invited a diverse group of supporters into the process from the beginning, asking them what a true West Ham beer should taste like, look like and stand for. After fan consultations produced a shortlist of names, supporters voted for Boleyn Brew — a proud nod to the Boleyn Ground and the memories, matchdays and moments that continue to unite generations of supporters.

BrewDog x West Ham

Supporters came back again and again to three ideas: history, heritage and unpretentious character. The result is a 4.5% Oat Lager with tropical fruit and citrus notes on a smooth, bready lager base — easy-drinking, full of character and made for the rituals that surround the game: meeting mates before kick-off, raising a pint on the concourse, watching from home or celebrating with the West Ham family. The can design features the iconic Boleyn Gates, connecting every pour back to the ground where so many supporters’ memories were made.

Stuart Harrison, Chief Sales Officer, BrewDog, said: “At BrewDog, we believe the best beers are built with the people who drink them. Boleyn Brew is exactly that: a beer shaped by West Ham fans from the first tasting conversation to the name on the can. It captures what makes this club special — heritage, passion, loyalty and a brilliant matchday atmosphere — and it is the kind of fan-first partnership we are proud to bring to life. We cannot wait to pour the first pints at London Stadium this weekend.”

Club legend Carlton Cole joined supporters throughout the consultation process, helping lead the conversation, taste the beer and bring the spirit of West Ham into the room. Cole was also the face of Claret & Brew, BrewDog and West Ham United’s first club-branded beer, which launched in November 2025 and sold out within hours.

Club legend Carlton Cole said: “After being part of Claret & Brew last season, I loved seeing the fans take this one even further and make a beer they can truly call their own. Boleyn Brew has the heart, loyalty and character of West Ham all over it. It is made by Hammers, for Hammers, and I cannot wait to raise a pint of our beer at London Stadium this weekend!”

West Ham United supporter Simon Fell, who was involved from the start of the process, said: “West Ham gets under your skin. It is the football, the people, the memories, the laughs, the tough days, the brilliant days and everything that comes with being a Hammer. From the start, it felt like supporters were genuinely part of creating something that belongs to us. Boleyn Brew feels properly West Ham: light, easy drinking, full of character and rooted in our history through the Boleyn Gates on the can. It is a beer for West Ham people, and I am proud to have played a small part in it. Our club, our memories, our beer. COYI!”

Fellow Hammer Elaine Hopkinson added: “A pint on matchday is part of the ritual — meeting family, friends and fellow fans, talking about the team and feeling that build-up before kick-off. To help create a beer made for West Ham fans by West Ham fans with BrewDog made it even more special. Boleyn Brew is a brilliant name: direct, proud and rooted in our heritage. The can design captures those iconic elements of the old ground perfectly.”

David Chaplin, Director of Commercial Strategy, West Ham United, commented: “BrewDog has put our supporters at the heart of this partnership, and Boleyn Brew is a brilliant example of what that can create. The engagement, energy and passion from our fans has been fantastic to see, and the final beer is something the West Ham family can be proud of. We are excited to launch it at London Stadium and continue working with BrewDog on experiences, activations and products that bring supporters closer to the club on matchdays and throughout the season.”

Boleyn Brew is the latest fan-first moment from BrewDog and West Ham United, building on a partnership designed to show up for supporters on and beyond matchday. The partnership launched in summer 2025, when BrewDog gifted full kits to grassroots teams across east London and Essex. Claret & Brew followed that November, alongside supporter benefits including free pints and discounts across BrewDog’s lineup. The partnership also forms part of BrewDog’s growing presence across the U.K.’s biggest sporting and live event venues, with BrewDog serving as exclusive beer partner of London Stadium and recently announcing a five-year partnership with Leicester Tigers.

Supporters can be among the first to try Boleyn Brew at the BrewDog container bar near Bridge 2 and at the BrewDog Deck at London Stadium from Saturday’s match against Southampton.

Limited-edition cans of Boleyn Brew are available now at www.brewdog.com while stock lasts.

About BrewDog
BrewDog has always had one mission: making people as passionate about great beer as we are. From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007. Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognizable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future will continue to be shaped by the three things that matter most: People, Planet and Beer.

For more information, visit www.brewdog.com or follow @BrewDog on social media.

About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

Tilray Brands Contacts:
Media
news@tilray.com

Investor Relations
investors@tilray.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/37ac36c6-fcf8-4122-a015-d3ae9cb5b270
https://www.globenewswire.com/NewsRoom/AttachmentNg/7fa17fb0-1734-402d-ba14-62744eac0f88

Posted in UncategorizedTagged GlobeNewswire

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Posted on October 21, 2026 by Ravi Shankar

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.

The Company expects named-patient access to be an important component of its international commercialization strategy for Ebstrocel™. Where permitted by local law and implemented through statements of work, this pathway may allow physicians to request Ebstrocel™ for individual eligible patients before local marketing approval or broad commercial availability.

The Uniphar framework is designed to provide the Company with scalable international commercial infrastructure, beginning with named-patient supply, and potentially expanding to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured in individual countries. Depending on the services agreed in individual statements of work, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking. By leveraging Uniphar’s established infrastructure rather than building country-by-country capabilities internally, the Company believes this model provides a capital-efficient path to establish Ebstrocel™’s international commercial footprint and scale as additional markets become available.

“This agreement marks an important step in moving Ebstrocel™ from clinical development toward commercialization and bringing Ebstrocel to patients internationally,” said David Moss, Chief Executive Officer of INmune Bio. “Uniphar provides access to established market-access, distribution and order-to-cash capabilities across multiple international markets without requiring INmune Bio to build those capabilities country by country. We believe this provides a capital-efficient way to pursue named-patient opportunities in appropriate markets while building the physician relationships, treatment-center experience and commercial infrastructure needed to support broader international commercialization.”

“We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”

About Ebstrocel™

Ebstrocel™ (pobistrocel) is INmune Bio’s investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through the Company’s CORDStrom™ platform for the treatment of RDEB. The platform is designed to address donor variability and manufacturing inconsistency. Ebstrocel™ is investigational and has not been approved by the FDA, MHRA, EMA or any other regulatory authority.

About Uniphar Plc.

Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide. With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.

Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.

Operating across 160 countries with a global team of 3,600+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.

From molecule to market and beyond.

For more information, please visit www.uniphar.com

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning toward regulatory and commercial readiness, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. regulatory pathway and development of international access and distribution infrastructure.
XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to reduce pathological neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates are investigational, and there can be no assurance that any clinical, regulatory or commercial objective will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, timing of key milestones, future plans or expectations, the scope and implementation of the Uniphar relationship, the execution of statements of work, the availability and timing of named-patient or expanded-access sales, potential revenue, potential expansion across Europe, the Middle East and North Africa (MENA) or into Latin America, the anticipated capital efficiency of the distribution model, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™ (Ebstrocel^TM, pobistrocel), XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com

Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com

Uniphar Contacts:
Media Contacts:
Uniphar: Heather.Hopkin@teamtala.com and Beth.Oshea@teamtala.com

Enquiries:
Uniphar: NPS_Ebstrocel@uniphar.com

Posted in UncategorizedTagged GlobeNewswire

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Posted on October 21, 2026 by Ravi Shankar

LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on October 20, 2026 stating that the Company currently complies with Listing Rule 5550(b)(1), requiring the Company to maintain stockholders’ equity of at least $2.5 million.

The Company previously reported the closing of its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. (“SOD”) and a 50% undivided co-ownership interest in SOD’s pseudohypoxia early-warning test. As part of the transaction, the Company issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000. The preferred stock is convertible at a fixed conversion price of $0.15 per share into up to 80,000,000 shares of common stock, subject to a 19.99% exchange cap, pending stockholder approval for lifting the cap, and an initial 4.99% beneficial ownership limitation. The preferred stock is expected to increase stockholders’ equity by more than $10 million, subject to the Company’s final purchase price accounting and review by the Company’s independent registered public accounting firm.

R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos, stated, “We are pleased to receive the compliance letter from Staff indicating that we are in compliance with Nasdaq’s Stockholders’ Equity Standard required for continued listing on the Nasdaq Capital Market. While the Company regained compliance with the stockholders’ equity requirement following the closing of the transaction with SOD, we continue executing our strategy to maintain compliance and grow our business.”

In its letter, the Staff stated that, based on the Company’s Current Report on Form 8-K filed on October 19, 2026, the Staff has determined that the Company is in compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The letter further stated that if the Company fails to demonstrate compliance upon the filing of its next periodic report, the Company may be subject to delisting, in which case the Staff would provide written notification to the Company, which could then appeal the Staff’s determination to a Nasdaq Hearings Panel.

About Vivos Therapeutics
Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company dedicated to developing and commercializing innovative diagnostic and treatment methods for patients experiencing breathing and sleep issues arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the expected increase in the Company’s stockholders’ equity and the anticipated accounting treatment of the Series C Convertible Preferred Stock and the acquired interests; the Company’s continued compliance with Nasdaq continued listing requirements; the anticipated revenue, margin and profit opportunities; and the projected advantages of the SOD transaction. Words such as “expects,” “believes,” “intends,” “potential,” “could,” “may,” “would,” “contemplated” and similar expressions identify forward-looking statements.

These statements are based on management’s current expectations and remain subject to risks and uncertainties that could cause actual results to differ materially, including, without limitation, the risks that: (i) the Company’s independent registered public accounting firm or Nasdaq reaches conclusions regarding the accounting treatment of the transaction or the Company’s stockholders’ equity that differ from those anticipated; (ii) the Company will be able to maintain such compliance, and the inability of the Company to maintain such compliance would lead to the delisting of the Company from Nasdaq; (iii) the Company does not regain or maintain compliance with Nasdaq’s other Nasdaq listing requirements; (iv) the anticipated revenue, margin and other benefits of the SOD transaction are not realized; (v) stockholder approval of the issuance of common stock upon conversion of the Series C Convertible Preferred Stock in excess of the exchange cap is not obtained; (vi) conversion of the Series C Convertible Preferred Stock results in dilution to existing stockholders; and (vii) the other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise such statements as result of new information, future events, or otherwise, except as required by law.

Investor and media contact
Vivos Therapeutics, Inc.: Investor Relations, investors@vivoslife.com

Posted in UncategorizedTagged GlobeNewswire

GOWell Energy Technology Reports Operating Subsidiary’s First Half 2026 Financial Results and Provides Corporate Update

Posted on October 21, 2026 by Ravi Shankar

Revenue in the first half of 2026 of $33.8 million, a 43% increase compared to the same period of 2025
Operating Profit was $9.1 million in the first half of 2026, a 135% increase compared to the same period of 2025
Net profit was $3.7 million in the first half of 2026, a 38% increase compared to the same period of 2025
For fiscal year 2026, the Company reiterates guidance for total revenue of $60 million to $68 million
Adjusted EBITDA in the first half of 2026 of $14.1 million, a 79% increase compared to the same period of 2025
GOWell completed its business combination with Inflection Point Acquisition Corp. V on September 25, 2026, and its ordinary shares began trading on Nasdaq on September 28, 2026 under the ticker symbol “GOW”

SINGAPORE and HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — GOWell Energy Technology (“GOWell” or the “Company”), a global one-stop shop for innovative well-logging solutions in the energy sector, today announced results of GOWell Technology Limited, a Cayman Islands exempted company (“GTL”) and a wholly-owned subsidiary of the Company, for the first half of 2026 and provided an update on its outlook for full year 2026 results. The historical financial results presented in this press release are those of GTL, the target operating company in that certain business combination transaction involving the Company, GTL and Inflection Point Acquisition Corp. V., prior to the effective date of such business combination.

“We are pleased to announce a strong start to the year as we generated significant growth across our business during the first half of 2026 with Revenue, Operating Profit and Adjusted EBITDA all displaying significant increases over the prior year,” commented Guillaume Borrel, GOWell’s Chief Executive Officer. “Our journey through 2026 to date has been defined by organizational development, strong operating results and positive momentum in our business which we expect to continue through the second half of 2026. Our business model and pipeline remain robust as our well-logging technologies bring impactful solutions to the global energy marketplace.”

“The continued execution of our strategic vision has led GOWell to new heights in 2026. Our strong financial performance across the first half of 2026 coincides with the closing of our business combination with Inflection Point and beginning of trading on the Nasdaq. Our transition into the public market gives us access to capital and the visibility to scale our platform as a trusted developer and provider of sensor solutions. We remain intently focused on advancing our objectives and delivering our solutions efficiently in this time of increased energy volatility,” added Mike Reed, GOWell’s Chief Financial Officer.

First Half 2026 Financial Summary of GOWell Technology Limited
Total revenue in the first half of 2026 increased 43% to $33.8 million compared to $23.6 million in the first half of 2025, primarily driven by an increase of $9.0 million in revenues from equipment sales and $1.2 million from service revenue. Operating profit increased by 135% to $9.1 million from $3.9 million. Net profit increased 38% to $3.7 million from $2.7 million, as higher operating profit was partly offset by $4.3 million in finance costs, primarily related to redeemable preferred shares, and a $1.6 million fair value loss on derivatives. Adjusted EBITDA, a non-IFRS metric, increased 79% to $14.1 million during the period, as compared to $7.9 million in the first half of 2025, supported by revenue growth and operating leverage.

Full Fiscal Year 2026 Outlook
GOWell reiterates total revenue guidance for the full fiscal year 2026 in the range of $60 million to $68 million, an increase of approximately 27% to 44% as compared to $47.2 million reported for fiscal year 2025. The Company also reiterates Adjusted EBITDA guidance for the full fiscal year 2026 in the range of $25 million and $29 million, an increase of approximately 40% to 63% as compared to $17.8 million reported for fiscal year 2025.

The above guidance was prepared based on numerous variables and assumptions which are inherently uncertain and may be beyond the control of GOWell. For more information regarding this guidance, its underlying assumptions and the reconciliation of non-IFRS financial measures, please see the sections entitled “The Business Combination—Certain Projected Financial Information” in the Company’s Proxy Statement/Registration Statement on Form F-4 filed in connection with the business combination, “Non-IFRS Financial Measures,” and “Forward-Looking Statements” below.

Non-IFRS Financial Measures
EBITDA and Adjusted EBITDA are non-IFRS financial measures used by our management to evaluate our operating performance. We believe that they provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors.

These non-IFRS financial measures are not defined under IFRS and are not presented in accordance with IFRS. They should not be considered in isolation or construed as an alternative to net profit or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review these historical non-IFRS financial measures in light of their most directly comparable IFRS measures, as shown below. The non-IFRS financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial
measure.

The table below sets forth the full reconciliation of GTL’s historical non-IFRS financial measures:

	For the Six Months Ended June 30,
	2026		2025
	(Unaudited)		(Unaudited)
	$000		$000
Net profit		3,699		2,680
Add:
Interest expense on loan		5		28
Interest expense on Company Preferred Shares		2,635		—
Interest expense on lease liability		117		127
Income tax expense		1,112		1,094
Depreciation and amortization expenses		3,499		2,897
EBITDA		11,067		6,826

Add:
Manufacturing Startup Costs		924		954
ERP Implementation Costs		175		—
Go Public Costs		369		106
Fair Value loss on derivatives		1,587		—
Adjusted EBITDA		14,122		7,886

The table below sets forth the full reconciliation of GOWell’s non-IFRS financial measures as projected:

	Year Ending December 31, 2026
	Low			High
	(Unaudited)			(Unaudited)
	$000			$000
Revenue		60,000			68,000

Net profit		5,912			8,845
Add:
Interest income on loan		(548	)		(548	)
Interest expense on loan		10			10
Interest expense on Company Preferred Shares		6,508			6,508
Interest expense on lease liability		234			234
Income tax expense		1,346			2,054
Depreciation and amortization expenses		7,492			7,856
EBITDA		20,954			24,959

Add:
Manufacturing Startup Costs		1,386			1,386
ERP Implementation Costs		325			325
Go Public Costs		750			750
Fair Value loss on derivatives		1,600			1,600
Adjusted EBITDA		25,015			29,020

Webinar Call Information
GOWell plans to host a webinar on Wednesday, October 21 at 10 a.m. Eastern Time to discuss the Company’s first half 2026 financial results and outlook. This webinar will be led by GOWell management including CEO Guillaume Borrel, CFO Mike Reed and VP of Corporate Development David MacNeill. To register for this webinar, please use the registration link found here. Additionally, for those unable to listen to the live webcast, a recording will be available following the live event on GOWell’s website at https://www.gowell.energy/.

About GOWell Energy Technology
GOWell Energy Technology is an international company that provides a wide range of innovative well-logging technologies and distributed sensing solutions for energy companies globally. The Company maintains a multi-disciplinary research and development team with a robust patent portfolio of technology aimed to solve complex industry challenges. GOWell’s solutions can be applied to a wide range of wells from traditional energy to energy transition. The Company has a global, diverse customer base with long-term relationships with the key major oil service companies and operators in the energy sector. Headquartered in Singapore, GOWell has a global manufacturing and procurement network, with regional hubs in the United States and UAE in addition to regional operations that cover more than 50 countries.

For more information about GOWell Energy Technology, visit https://www.gowell.energy/.

Forward Looking Statements
This press release includes or may include “forward-looking statements” regarding, among other things, the plans, strategies and prospects, both business and financial, of GOWell Energy Technology and its subsidiaries. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “predicts,” “projects,” “forecasts,” “may,” “might,” “will,” “could,” “should,” “would,” “seeks,” “plans,” “scheduled,” “possible,” “continue,” “potential,” “anticipates” or “intends” or similar expressions; provided that the absence of these does not mean that a statement is not forward-looking. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur, and our actual results could differ materially from those anticipated in these forward-looking statements.

Important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include: general economic, political and business conditions; the outcome of any legal proceedings that may be instituted against the Company or its subsidiaries; the Company’s capitalization and the market value of its securities following the consummation of the Business Combination; the ability of GOWell to issue equity, equity-linked or other securities in the future; the ability of the Company to realize the anticipated benefits of the Business Combination; the risks related to the rollout of GOWell’s business and the timing of expected business milestones; the ability of GOWell to execute its growth strategy, manage growth profitably and retain its key employees; the ability of GOWell to maintain the listing of its securities on the Nasdaq Stock Market LLC following the Business Combination; and other risks and uncertainties indicated in the Proxy Statement/Prospectus filed in connection with the Business Combination and in GOWell’s other filings with the U.S. Securities and Exchange Commission. Undue reliance should not be placed upon the forward-looking statements.

These forward-looking statements are made only as of the date of this press release. The Company does not undertake any obligation to publicly update or revise any forward-looking statement contained in this press release, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations Contact:
Gateway Group
Georg Venturatos, Patrick Hall
949-574-3860
GOWell@gateway-grp.com

Media Relations Contact:
Gateway Group
Zach Kadletz, Ryan Deloney
949-574-3860
GOWell@gateway-grp.com

GOWELL TECHNOLOGY LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCE POSITION (Amounts in U.S. Dollars, except for number of shares)

		As of June 30, 2026			As of December 31, 2025
	Unaudited
Assets
Current assets
Cash and cash equivalents	$	2,910,012		$	6,751,021
Restricted cash		201,596			10,000
Trade receivables, net		25,737,317			18,008,048
Inventories, net		17,197,546			15,569,533
Amounts due from related parties		49,941			44,405
Long-term receivables, current		511,884			551,302
Deferred offering costs		2,937,959			2,614,409
Prepaid expenses and other current assets		3,422,311			1,915,525
Total current assets		52,968,566			45,464,243

Non-current assets
Rental equipment, net		22,987,058			22,761,997
Property and equipment, net		3,955,436			1,984,734
Intangible assets, net		5,087,694			2,792,272
Right-of-use assets, net		5,145,360			5,614,107
Long-term receivables, net		—			28,489
Deferred tax asset, net		3,666,142			3,318,591
Other non-current assets		556,649			488,715
Total non-current assets		41,398,339			36,988,905
Total Assets	$	94,366,905		$	82,453,148

LIABILITIES AND EQUITY

LIABILITIES
Current liabilities
Trade payables	$	4,009,799		$	789,134
Trade payables – related parties		5,118,377			4,104,133
Accruals and other payables		6,129,848			4,860,484
Loans payable, current		24,877			25,149
Amounts due to related parties, current		83,179			80,231
Income tax payable		1,875,857			1,513,137
Operating lease liabilities, current		1,731,623			1,684,479
Total current liabilities		18,973,560			13,056,747

Non-current liabilities
Loans payable, non-current		23,367			37,262
Amount due to a related party-non-current		—			386,042
Derivative liabilities		6,986,124			5,399,140
Redeemable preference shares		18,356,511			16,663,052
Deferred tax liabilities		68,298			—
Operating lease liabilities, non-current		4,129,338			4,702,317
Total non-current liabilities		29,563,638			27,187,813
Total Liabilities		48,537,198			40,244,560

EQUITY
Share capital		3,000			3,000
Additional paid-in capital		29,164,781			29,164,781
Retained earnings		16,793,800			13,094,403
Accumulated other comprehensive loss		(131,874	)		(53,596	)
Total Equity		45,829,707			42,208,588
Total Liabilities and Equity	$	94,366,905		$	82,453,148

GOWELL TECHNOLOGY LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Amounts in U.S. Dollars, except for number of shares)

	For the six months ended June 30,
	2026			2025
	Unaudited			Unaudited
Revenues – third parties	$	33,476,516		$	22,017,408
Revenues – related parties		284,216			1,545,067
Total revenues		33,760,732			23,562,475
Cost of revenues		(13,980,807	)		(9,715,975	)
Gross profit		19,779,925			13,846,500

OPERATING EXPENSES:
Selling and marketing expenses		(3,271,668	)		(3,273,788	)
General and administrative expenses		(6,750,787	)		(4,660,492	)
Research and development expenses		(623,322	)		(2,021,828	)
Total operating expenses		(10,645,777	)		(9,956,108	)

Operating profit		9,134,148			3,890,392

OTHER EXPENSES:
Finance income		9,570			119,845
Finance cost		(4,343,318	)		(154,367	)
Other income, net		10,646			(81,370	)
Total other expenses		(4,323,102	)		(115,892	)

Profit before income tax expense		4,811,046			3,774,500
Income tax expense		(1,111,649	)		(1,094,281	)
Net profit		3,699,397			2,680,219

OTHER COMPREHENSIVE INCOME
Foreign currency translation adjustments		(78,278	)		101,374
Total comprehensive income	$	3,621,119		$	2,781,593

Net profit per ordinary share
Basic and Diluted		0.12			0.09

Weighted average number of ordinary shares outstanding
Basic and Diluted		30,000,000			30,000,000

Posted in UncategorizedTagged GlobeNewswire

REGO Guardian Gives Platforms Verified Parental Consent Through a Single API

Posted on October 21, 2026 by Ravi Shankar

Platforms get one signed answer (age band, permissions, pseudonym, expiry) with no child PII; new AI protections are designed to help stop harmful conversations before they reach kids

BLUE BELL, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) — REGO Payment Architectures, Inc. (OTCQB: RPMT) today announced the expansion of its REGO Guardian Global Solution with an API service that digital platforms integrate to get verified parental consent and age assurance.

A parent verifies their relationship with their child once. When the child tries to join or use a participating platform, the parent approves, limits or denies, and the platform gets one signed answer it can verify: the child’s age band, the permissions granted, a per-platform pseudonym and an expiry. The platform never receives the child’s name, birthday, photo or other personal information. The initiative is built on Rego Guardian’s October 15 global SaaS licensing initiative

REGO is also developing AI classification designed to help platforms detect grooming and exploitation patterns in real time and enforce parent-set boundaries before harmful messages reach a child.

Moving Beyond Parental Controls to Proactive AI Protection

Traditional parental controls have largely focused on screen time, application restrictions, and content filtering. But the rapid expansion of conversational AI, personalized gaming companions, and autonomous digital agents introduces an entirely new category of risk.

Today’s AI systems can maintain ongoing conversations, remember previous interactions, personalize responses based on user behavior, and access increasingly sensitive information.

REGO Guardian’s agentic AI architecture is designed to recognize these emerging risks and empower verified guardians to determine what types of communications, interactions, and data access are permissible.

Through platform integrations, guardians could establish personalized restrictions addressing:

Sexual grooming and exploitation: Detecting potentially predatory conversational patterns, coercion, inappropriate relationship-building, and sexual solicitation.
Financial fraud and manipulation: Identifying suspicious financial requests, scams, sextortion, and attempts to obtain sensitive information.
Harmful AI interactions: Restricting conversations involving self-harm encouragement, inappropriate emotional dependency, manipulation, or other high-risk behaviors.
Privacy and sensitive data: Applying age-appropriate limitations to the collection, processing, or sharing of behavioral information, location data, biometric identifiers, and other sensitive information.
Guardian-defined communication boundaries: Allowing parents to establish individualized policies based on their children’s ages, needs, and family values.

Depending on the participating platform’s capabilities and approved integration, classified interactions could be permitted, limited, withheld, or escalated for appropriate review before being delivered to the child.

Unlike systems limited to notifying parents after an incident, the REGO Guardian framework is designed to support preventive intervention.

Solving a Critical Gap in the Agentic AI Economy

As gaming, financial services, social media, and technology companies increasingly deploy autonomous AI agents, they face a fundamental governance challenge.

Enterprise AI gateways can determine whether an agent is authorized to access a particular application, database, or service. But those systems also need reliable information about the human being served, including whether that person is a minor and whether parental authorization applies.

REGO Guardian is designed to provide that missing trust layer.

REGO Guardian’s goal is to connect what the AI agent is technically capable of doing with what it is authorized to do for a particular user.

Leadership Perspective

Dr. Lisa Strohman, JD, PhD, Head of Product, REGO Guardian

“Artificial intelligence is changing childhood faster than parents can keep up. We are entering a world where AI agents can build relationships with children, remember their vulnerabilities, influence their emotions, and engage in conversations that may lead to exploitation or serious psychological harm. We cannot continue asking parents to protect their children with tools that only alert them after the damage is done.

REGO Guardian represents a fundamental shift from reacting to harm to preventing it. By combining verified parental authority with AI-powered safety intelligence, we are building technology designed to recognize dangerous interactions and enforce family-defined boundaries before harmful content reaches a child. Our mission is simple: give parents the ability to protect their children without sacrificing their children’s privacy, independence, or opportunity to benefit from technology.”

Peter S. Pelullo, Chief Executive Officer, REGO Payment Architectures

“The rapid expansion of agentic AI is creating a new and significant infrastructure market. Companies are investing billions in autonomous technologies, yet age verification, parental authority, and child-specific policy enforcement remain fragmented.

“REGO Guardian is positioned to provide the interoperable trust infrastructure connecting these capabilities across platforms and industries. By combining our proprietary verification architecture with AI-driven protection, we believe we are addressing a critical need for technology companies seeking to build trusted, scalable, and commercially sustainable digital environments.”

A New Foundation for Digital Trust

As agentic systems become increasingly integrated into consumer applications, REGO believes these capabilities could become an important component of future digital trust infrastructure.

Platforms develop the technology. Parents establish the boundaries. REGO Guardian is designed to connect the two.

About REGO Guardian

REGO Guardian, developed by REGO Payment Architectures, Inc. (OTCQB: RPMT), is an integrated digital trust and child-safety solution designed to bring together patented age assurance, verified parental authority, portable permission credentials, privacy-preserving architecture, and AI-powered contextual risk assessment. REGO Guardian is COPPA certified and GDPR compliant.

Learn more at www.regoguardian.com.

Media Contact

REGO Payment Architectures, Inc.
Donald Tremblay
dtremblay1006@gmail.com

Investor Relations

Peter L. Seltzberg
pseltz5starir@gmail.com

Posted in UncategorizedTagged GlobeNewswire

Magna Mining Reports Results of Crean Hill Pre-Feasibility Study With Construction to Begin in 2027

Posted on October 21, 2026 by Ravi Shankar

SUDBURY, Ontario, Oct. 21, 2026 (GLOBE NEWSWIRE) — Magna Mining Inc. (TSX: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to announce the results of a Pre-Feasibility Study (“PFS”) prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) for the 100% owned Crean Hill Project (“Crean Hill”), located in the South Range of the Sudbury Basin, northeastern Ontario. All amounts are expressed in Canadian dollars unless otherwise indicated.

Crean Hill PFS Highlights:

Twelve-year commercial mine life with over 11 million tons of probable reserves: The Crean Hill PFS contemplates underground mining of 11.4 million tons of probable reserves at an average mining rate of approximately 2,400 tons per day during the twelve-year commercial mine life.
Robust production profile with significant precious metals byproduct credits: Average annual payable copper equivalent (“CuEq”)^1,2 production of 35.5 million pounds (“lbs”) during commercial production at all-in sustaining costs (“AISC”) of US$3.55 per CuEq payable lb, including 42 thousand ounces of precious metals (platinum + palladium + gold) on average per year which contribute approximately 38.9% of revenues during this time.
Attractive base case economics with strong commodity price leverage: Assuming base case commodity prices¹, the Crean Hill PFS estimates payback in 1.5 years with an after-tax Internal Rate of Return (“IRR”) of 43.4% and an after-tax NPV7% of $251.0 million. Pre-tax cash flows average approximately $65.2 million per year and increase to $96.2 million per year using September 2026 average commodity prices¹, while the after-tax NPV7% increases to $406.1 million, the IRR improves to 65.4%, and the payback period falls to 0.8 years.
Manageable initial capital spread over a three-year pre-commercial production period: Initial capital costs from January 1, 2027 are estimated to be $127.0 million. This initial capital is expected to be offset by refundable tax credits³ of $17.2 million and pre-commercial production operating cash flow of approximately $37.4 million using base case price assumptions, leaving a calculated net initial funding requirement of $72.4 million. Construction spending is expected to ramp up gradually over a three-year period with first ore sales in late 2027 and commercial production achieved in early 2030.
Positive potential impact from the recently announced Productivity Mega Deduction: Incorporation of the Productivity Mega Deduction (“PMD”)⁴ could reduce the estimated federal taxes payable over the life of mine, especially during the early years of commercial production. By accelerating the utilization of certain tax deductions via the PMD, the Crean Hill PFS after-tax NPV7% would improve by $5.7 million to $256.7 million and the IRR would increase to 45.5%.

Crean Hill construction to commence in 2027: Based on the results of the PFS (summarized in Table 1), the Company’s Board of Directors has approved construction of the Crean Hill project, which will commence in 2027. In the interim, the Company will continue with detailed engineering work, surface site preparations including installation of grid power and recruitment of additional personnel.

Crean Hill exploration drilling now underway: In addition, an exploration diamond drill rig has been mobilized to the Crean Hill Project and has started drill testing new targets for additional footwall copper and precious metals-rich mineralization.

¹Base case price assumptions: US$5.10/lb Cu, US$8.00/lb Ni, US$20.00/lb Co, US$3,600/oz Au, US$1,500/oz Pt, US$1,200/oz Pd, US$45.00/oz Ag; CAD/USD $1.385. Illustrative spot price case assumptions based on September 2026 average prices: US$6.55/lb Cu, US$7.50/lb Ni, US$24.90/lb Co, US$4,320/oz Au, US$1,785/oz Pt, US$1,310/oz Pd, US$64.50/oz Ag; CAD/USD $1.370.
² Payable CuEq production considers base case price assumptions and modeled recovery and payabilities for each metal.
³ Assumes $17.2 million in refundable tax credits via the Clean Technology Manufacturing Investment Tax Credit (CTM-ITC).
⁴ On September 15, 2026, the Canadian federal government announced the Productivity Mega Deduction (“PMD”), allowing businesses to immediately deduct the cost of a broad range of capital assets, rather than claiming those deductions over time. The PMD is subject to legislative approval.

Jason Jessup, CEO of Magna Mining, stated, “We are pleased to announce the results of the Crean Hill PFS, which demonstrates robust economics and a clear path toward construction. The base case delivers an after-tax IRR of 43.4% and a 1.5-year payback period. Crean Hill also benefits from a balanced mix of copper, nickel and precious metals production, providing meaningful exposure to seven payable metals without an overreliance on any single commodity.

The PFS outlines a 12-year commercial mine life and C$72.4 million of net initial funding after refundable tax credits and pre-commercial production operating cash flow. The development plan builds on the core approach established in the 2024 Crean Hill PEA—advancing a new ramp from surface before re-establishing shaft hoisting—and leverages the project’s brownfield setting and existing infrastructure. On the strength of these results, our Board has approved moving forward with construction in 2027. In the interim, our team will continue detailed engineering and design, advance procurement of long-lead items, site preparation and recruitment of the additional people needed to execute the plan. We are also excited to have initiated exploration drilling at Crean Hill for the first time since 2024. I would like to thank everyone whose work and commitment have advanced the project to this important milestone.”


Table 1: Key Crean Hill PFS Project Metrics

Production Profile		Unit
Commercial Mine Life	12.0	years
Mining rate¹	2,397	tons per day
Total mined ore (Probable Reserve)	11,358,861	tons
CuEq head grade^1,5	2.99%
Avg. annual copper production¹	9.5	million payable lbs
Avg. annual nickel production¹	7.5	million payable lbs
Avg. annual precious metals production¹	42.0	koz Pt+Pd+Au payable
Avg. annual CuEq production^1,5	35.5	million payable lbs
Operating Costs		Unit
Production costs LOM	$152.62	C$ per ton processed
Total cash costs LOM	US$3.10	US$ per CuEq payable lb
All-in sustaining costs LOM	US$3.55	US$ per CuEq payable lb
Capital Costs
Initial capital²	$127.0	C$ million
Refundable tax credits	-$17.2	C$ million
Pre-commercial production operating cash flow	-$37.4	C$ million
Net initial funding	$72.4	C$ million
LOM sustaining capital	$261.7	C$ million
Project Economics	Base Case³	Spot Price Case⁴
Avg. annual operating cash flow¹ (C$ million)	C$87.3 M	C$118.3 M
Pre-tax NPV7% (C$ million)	C$329.7 M	C$554.3 M
After-tax NPV7% (C$ million)	C$251.0 M	C$406.1 M
After-tax IRR	43.4%	65.4%
After-tax cash flow LOM (C$ million)	C$507.8 M	C$779.2 M
After-tax payback period	1.5 years	0.8 years
After-tax NPV7% with PMD⁶ (C$ million)	C$256.7 M	C$412.4 M
After-tax IRR with PMD⁶	45.5%	68.0%

¹Production averages cover commercial production from Years 4-15. CuEq head grade is on a contained basis covering Life of Mine, CuEq determined using base case metal price assumptions. Tons are short tons (2,000 lb).
²Year 1-3 pre-commercial production capital, after equipment financing timing effect; before operating cash flow and refundable tax credits. Payback is measured from end of Year 3.
³US$5.10/lb Cu, US$8.00/lb Ni, US$20.00/lb Co, US$3,600/oz Au, US$1,500/oz Pt, US$1,200/oz Pd, US$45.00/oz Ag; CAD/USD $1.385.
⁴Illustrative spot-price case based on September 2026 average prices: US$6.55/lb Cu, US$7.50/lb Ni, US$24.90/lb Co, US$4,320/oz Au, US$1,785/oz Pt, US$1,310/oz Pd, US$64.50/oz Ag; CAD/USD $1.370.
⁵See Tables included with Figures 2 and 3 for grades and contribution of specific metals.
⁶On September 15, 2026, the Canadian federal government announced the proposed Productivity Mega Deduction (“PMD”), which would permit the immediate deduction of certain eligible capital expenditures for income tax purposes. As the PMD has not yet been enacted into law, the benefit has been excluded from the base-case economic analysis and is presented separately as a sensitivity.

Figure 1: Location of Crean Hill and Key Sudbury Infrastructure

PFS Overview

The Crean Hill project, located in the South Range of the Sudbury Basin (Figure 1), is a brownfield redevelopment of the past-producing nickel-copper-precious metals (platinum, palladium, gold, silver) Crean Hill Mine. Since 1906, the Crean Hill mine site underwent multiple phases of open-pit and underground mining with the most recent operations having ceased in 2002. During this period, approximately 20.4 million tonnes of ore were produced at an average grade of 1.31% nickel, 1.09% copper, and 1.56 g/t total precious metals (platinum + palladium + gold). The underground workings have subsequently flooded, and all surface infrastructure dismantled. In November 2022, the Company acquired Lonmin Canada Inc., including the past-producing Crean Hill Mine. The Company holds the mining rights from the top of the existing concrete capped Shaft #2 (former historic Crean Hill Mine production shaft) to a depth of 4,500 feet (1,372 metres). Vale Canada Limited (Vale) continues to hold all Mining Rights below 4,500 feet. Topics covered in the PFS include the mining design basis, geotechnical design basis, hydrogeology and dewatering, mine access and design, mining method and stope design, development, production schedule, metallurgy, mobile fleet, workforce, ventilation, backfill, material handling and grade control. The PFS was prepared by SGS Geological Services (SGS) with the assistance of Magna’s Projects team, as well as insights from current operations at the Company’s McCreedy West Mine in Sudbury. The PFS incorporates geological information collected by the Company including 199 diamond drill holes for a total of 44,895 metres of drilling between November 2022 and December 2024, the results from the 20,000 tonne bulk sample program executed in the second half of 2024, as well as historic information from the previous underground mining operations at Crean Hill.

Mine Plan and Production Schedule

The Crean Hill PFS mine plan (summarized in Table 1) envisions an underground mining operation, with the probable reserves being hauled and sold to an existing third-party mill in Sudbury. Initial mining is contemplated by ramp access via a new surface portal with the eventual rehabilitation and re-establishment of the historic Shaft #2 for ore hoisting as mining progresses deeper. The PFS assumes go-forward capital spending begins on January 1, 2027 and ramps up over the first three years with initial ore generated towards the end of Year 1 and commercial production anticipated at the end of Year 3 (Figure 2). At the target commercial production rate of approximately 2,400 short tons per day, the mine plan includes 11.4 million short tons over a 12.0 year mine life.

The mineralized zones incorporated in the PFS mine plan include both contact ore (including the Main, Intermediate, 99 and 9400 Zones) as well as footwall ore (the 109 FW Zone). The 11.4 million short tons of probable reserves are derived from the current Crean Hill Mineral Resource Estimate.

Figure 2 shows annual mill feed by ore type and contained CuEq head grade. During commercial production (Years 4-15), ore shipped and processed averages 875,000 tons per year. The contained CuEq head grade uses base case metal prices, without recovery, payability, or cost deductions and averages 2.99% CuEq over the twelve-year commercial mine life. Figure 3 shows payable metal production expressed as CuEq, using the modeled recoveries and payabilities. Precious metal head grades in Figure 2 are in grams per tonne. Annual payable metal production during the twelve-year commercial mine life averages 35.5 million lbs CuEq, comprised of 9.5 million lbs copper, 7.5 million lbs nickel, 6,400 oz gold, 15,600 oz platinum, and 19,900 oz palladium.

Figure 2: Crean Hill PFS Production Schedule & Contained Copper Equivalent Grade

Year		Y 1	Y 2	Y 3	Y 4	Y 5	Y 6	Y 7	Y 8	Y 9	Y 10	Y 11	Y 12	Y 13	Y 14	Y 15
Ore shipped (short tons)		8,139	401,572	450,372	887,305	887,056	887,533	888,744	887,497	887,557	888,088	887,387	832,259	887,188	888,906	789,259
Contained Grades	CuEq (%)	2.05	3.12	2.96	3.04	3.34	3.78	2.87	2.56	2.92	2.82	2.76	3.13	2.81	3.18	2.67
	Cu (%)	0.49	0.77	0.71	0.68	0.56	0.53	0.60	0.57	0.69	0.69	0.68	0.68	0.51	0.57	0.57
	Ni (%)	0.59	1.01	0.80	0.70	0.59	0.52	0.68	0.68	0.79	0.81	0.76	0.56	0.57	0.58	0.56
	Co (%)	0.02	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.03	0.02	0.02	0.02	0.02
	Au (gpt)	0.21	0.25	0.33	0.39	0.61	0.68	0.32	0.22	0.27	0.24	0.22	0.59	0.47	0.66	0.31
	Pt (gpt)	0.43	0.57	0.74	0.87	1.31	1.93	0.96	0.73	0.66	0.62	0.65	1.00	1.09	1.20	0.92
	Pd (gpt)	0.39	0.35	0.61	1.09	1.69	2.30	1.04	0.80	0.94	0.68	0.78	1.30	1.09	1.17	1.16
	Ag (gpt)	0.96	0.87	1.31	0.74	1.07	2.84	0.83	0.57	0.99	1.05	1.23	0.58	0.55	1.46	0.97

Figure 3: Crean Hill PFS Copper Equivalent Payable Metal Production

Year		Y 1	Y 2	Y 3	Y 4	Y 5	Y 6	Y 7	Y 8	Y 9	Y 10	Y 11	Y 12	Y 13	Y 14	Y 15
Payable Metal	CuEq (million lb)	0.21	17.33	18.09	36.92	40.90	46.60	34.35	29.88	35.16	33.77	32.84	35.76	33.46	38.53	27.96
	Cu (million lb)	0.07	5.51	5.69	10.78	8.93	8.37	9.57	9.05	10.97	10.85	10.73	10.10	8.11	9.07	8.06
	Ni (million lb)	0.06	5.92	5.06	8.42	6.62	5.63	8.04	8.13	9.70	10.10	9.26	5.84	6.38	6.60	5.61
	Co (million lb)	0.001	0.060	0.051	0.084	0.068	0.058	0.088	0.088	0.092	0.102	0.092	0.060	0.064	0.067	0.064
	Au (koz)	0.024	1.458	2.472	6.102	10.366	11.844	4.642	2.654	3.537	2.942	2.680	9.436	7.626	11.376	3.982
	Pt (koz)	0.041	3.109	5.156	13.511	22.553	34.929	15.251	10.115	8.636	7.853	8.596	15.124	17.983	20.282	12.937
	Pd (koz)	0.038	1.500	4.223	18.343	31.352	43.774	17.256	12.274	15.145	9.746	11.897	21.892	18.767	20.659	18.034
	Ag (koz)	–	–	–	–	–	27.941	–	–	–	–	–	–	–	–	–

Capital and Operating Costs

The Crean Hill Project is a former operating mine site with existing infrastructure such as year-round access, nearby electrical power line grid, and available water sources. Pre-existing infrastructure as well as capital invested prior to the end of 2026 is treated as sunk capital for the purposes of the PFS.

Estimated initial capital is $127.0 million, including $17.9 million of contingency. The estimate comprises capital expenditure from January 1, 2027 to the start of commercial production at the end of Year 3, reflecting the timing of equipment financing (Table 2). Estimated initial capital is presented after equipment financing timing effects. Deferred equipment purchase payments are included in subsequent years. Initial capital is estimated to be $33.0 million in Year 1, $35.0 million in Year 2, and $59.0 million in Year 3. The after-tax cash flow model incorporates the Clean Technology Manufacturing investment tax credits. Eligibility and receipt of those credits remain subject to the applicable requirements and the Company’s tax review. While pre-commercial production operating cash flow and the benefit of refundable tax credits does not reduce the initial capital required, it does help to decrease the net cash outlay at the end of the ramp-up period to an estimated $72.4 million.

Estimated sustaining capital from commercial production at the end of Year 3 onward is $261.7 million.


Table 2: Crean Hill Initial Capital Costs

Initial Capex	C$ million
Mining Capital
Underground development	$35.0
Mobile fleet (after financing timing effects)	$38.9
Underground infrastructure	$8.7
Subtotal	$82.6
Surface Infrastructure Capital
Ventilation	$2.9
Water management	$3.3
Power distribution & substation	$2.9
Backfill plant & reticulation	$4.4
Other surface facilities	$1.9
Subtotal	$26.4
Contingency	$17.9
Total initial capital (Year 1-3)¹	$127.0
Refundable tax credits	-$17.2
Pre-commercial production operating cash flow	-$37.4
Net initial funding	$72.4

¹ Figures may not sum exactly due to rounding

The Company’s producing McCreedy West Mine is also located in Sudbury and provides an operating cost and productivity benchmark. Average life-of-mine operating costs in the Crean Hill PFS are $152.62 per short ton processed (Table 3). Cash costs are US$3.10/lb payable CuEq and AISC are US$3.55/lb payable CuEq. Cash costs and AISC use the commercial production periods and AISC includes estimated sustaining capital. These are non-GAAP measures and may not be comparable with similarly named measures used by other companies.


Table 3: Crean Hill PFS Operating Costs

Operating Costs	LOM	Unit
Mining costs	$77.47	C$/ton shipped
Surface & processing costs	$57.04	C$/ton shipped
General & site administration costs	$18.11	C$/ton shipped
Total Operating Costs	$152.62	C$/ton shipped
Total Cash Costs	US$3.10	US$/lb CuEq payable
AISC	US$3.55	US$/lb CuEq payable

Project Economics & Sensitivity

At the base-case prices in Table 4, recovered payable metal value comprises the following revenue share 27.3% copper, 34.4% nickel, 12.4% gold, 12.5% platinum, 12.5% palladium, 0.9% cobalt, 0.1% silver. The average annual revenue during commercial production is $223.4 million while pre-tax cash flows average approximately $65.2 million per year (Figure 4). The Crean Hill PFS base case pre-tax NPV7% is $329.7 million and the after-tax NPV7% is $251.0 million, with an after-tax IRR of 43.4% and payback of 1.5 years. The after-tax NPV7% incorporates the Company’s current tax assumptions, including an estimated benefit of $40.0 million LOM from the Clean Technology Manufacturing investment tax credit. The realization of this tax benefit remains subject to the Company’s ability to satisfy the applicable legislative and tax filing requirements.

An illustrative spot-price case scenario based on average metal prices during September 2026 returns a pre-tax NPV7% of $554.3 million, an after-tax NPV7% of $406.1 million, an after-tax IRR of 65.4% and payback of 0.8 years. The average annual revenue during commercial production in the spot-price case scenario is $255.1 million while pre-tax cash flows would average approximately $96.2 million per year. Tables 4 and 5 and Figure 5 show fixed mine plan sensitivities. Price-only sensitivities hold the base exchange rate constant; the illustrative spot case applies USD/CAD 0.730 to revenue and U.S. dollar milling charges, with other cost translations held at the base case rate.

The base case after-tax economic results exclude any benefit associated with the PMD tax incentive. For illustrative purposes, a separate tax sensitivity was completed assuming the Company is eligible to claim available PMD deductions on qualifying expenditures. Under this scenario, the base case after-tax NPV7% increases to $256.7 million and the after-tax IRR increases to 45.5%. This legislation remains subject to approval.

Figure 4: Crean Hill PFS Pre-Tax Cash Flow


Table 4: Crean Hill PFS Economic Summary & Sensitivity Analysis

Price Deck	Unit	-10%	Base Case	+10%	Spot Price Case
Copper	US$/lb	$4.59	$5.10	$5.61	$6.65
Nickel	US$/lb	$7.20	$8.00	$8.80	$7.55
Gold	US$/oz	$3,240	$3,600	$3,960	$4,400
Platinum	US$/oz	$1,350	$1,500	$1,650	$1,850
Palladium	US$/oz	$1,080	$1,200	$1,320	$1,350
Silver	US$/oz	$40.50	$45.00	$49.50	$65.00
Cobalt	US$/lb	$18.00	$20.00	$22.00	$22.00
USD/CAD	x	0.722	0.722	0.722	0.730
LOM Economics
Revenue LOM	C$ million	$2,572.3	$2,896.6	$3,220.8	$3,300.7
Operating cash flow LOM	C$ million	$765.0	$1,079.5	$1,394.0	$1,475.6
Pre-tax cash flow LOM	C$ million	$362.5	$677.0	$991.5	$1,073.1
After-tax cash flow LOM	C$ million	$291.7	$507.8	$723.4	$779.2
Annual Averages (Commercial Production)
Revenue	C$ million per year	$198.5	$223.4	$248.4	$255.1
Operating cash flow	C$ million per year	$63.1	$87.3	$111.5	$118.3
Pre-tax cash flow	C$ million per year	$41.0	$65.2	$89.4	$96.2
After-tax cash flow	C$ million per year	$33.1	$49.1	$65.0	$69.7
Net Present Value & IRR
Pre-tax NPV7%	C$ million	$149.9	$329.7	$509.6	$554.3
After-tax NPV7%	C$ million	$125.6	$251.0	$375.6	$406.1
Pre-tax IRR	%	23.5%	42.7%	62.4%	65.5%
After-tax IRR	%	25.1%	43.4%	62.8%	65.4%
Payback	years	2.3	1.5	0.8	0.8
After-tax NPV7% / initial capex	x	1.0x	2.0x	3.0x	3.2x
After-tax NPV7% with PMD	C$ million	$130.6	$256.7	$381.8	$412.4
After-tax IRR with PMD	%	26.6%	45.5%	65.5%	68.0%

Table 5: Base Case After-tax NPV7% Sensitivity Analysis (C$ million)

Change	-20%	-10%	0%	10%	20%
Copper	$183.9	$217.4	$251.0	$284.5	$317.9
Nickel	$162.8	$206.9	$251.0	$294.9	$338.7
Metal prices	-$3.7	$125.6	$251.0	$375.6	$499.2
Operating costs	$389.3	$320.4	$251.0	$181.3	$111.2
Capital costs	$306.5	$278.7	$251.0	$223.2	$195.4

Figure 5: Sensitivity Analysis

Mining, Processing and Infrastructure

As illustrated in Figure 6, the PFS adopts an underground bulk longhole mining method with access to both transverse and longitudinal stopes via ramps and drifts suitable for medium-to-large-size diesel-powered mobile equipment. Sublevel spacing varies between 80 and 115 feet vertically. Access to the underground workings will be established in a phased approach. Initially, a box cut and portal will be constructed and an access ramp developed to support initial production from the upper portion of the mine. Ore will be generated prior to commercial production from areas above the 500 Level and will rely mostly on repair and rehabilitation of existing ventilation and service raises. Mining above the 2000 Level will rely exclusively on a fleet of 50-ton haul trucks bringing ore, and waste as necessary, to surface up the ramp. As mining progresses deeper, reliance on newly excavated ventilation and egress raises along with the eventual reconstruction of a surface hoisting plant and shaft repair will allow ore to be hoisted from the 2000 Level shaft loading pocket. This will reduce the need for a larger haul truck fleet and the associated mine ventilation upgrade over the life of mine.

Longhole drilling will use self-propelled electric-hydraulic machines, and production blasting will be done with almost exclusively emulsion-type explosives. Mined-out stopes will be backfilled with a combination of unconsolidated rock fill, cemented sand fill and hydraulic fill depending on mining sequence and the availability of suitable waste rock over the course of mine life.

In addition to basic surface infrastructure that will include shop, office and warehousing facilities, a sandfill plant, crushing and sampling tower and eventually a hoist & muck transfer system will be constructed, as well as conventional mine air ventilation and heating infrastructure.

Provision within the life of mine plan has been made for upgrades to the water treatment system associated with discharge to the environment from site. First by the installation of clarifiers to replace the existing pilot plant solids capture system, and eventually a more complex system to manage more complex chemicals.

Once on surface, ore will be reduced to a topsize of 1.5 inches via a contractor-operated surface crusher comprised of a combination of a jaw crusher (until hoisting begins) and cone crusher and then subsampled via the onsite sampling tower with representative subsamples dispatched to the sample preparation and analytical laboratory. Production lots of approximately 2,000 to 4,000 tons of ore will then be shipped to third party milling facilities located in Sudbury, Ontario.

Figure 6: Crean Hill Infrastructure and Geological Zones

Mineral Resources and Mineral Reserves

The Crean Hill Mineral Resource Estimate is presented below in Table 6 and is based on a 1.75% CuEq cutoff grade. The current Mineral Resources have been updated from the November 1, 2024 Mineral Resources stated in the Preliminary Economic Assessment, and have an effective date of April 15, 2026, which is the close out date for the final mine out models (as-builts) used to deplete historical mining. The underlying resource model parameters and drillhole database remains unchanged from the 2024 model, however the cutoff grade has been updated to 1.75% CuEq, based on the metal prices stated below and the model has been depleted with a more detailed mine-out model, to more accurately account for historical mining. Mineral Resources are inclusive of those resources which have been converted to Mineral Reserves. Allan Armitage, Ph.D., P. Geo. of SGS Geological Services is an independent Qualified Person as defined by NI 43-101 and is responsible for the current Crean Hill Mineral Resource Estimate.

Table 6: Crean Hill Mineral Resource Estimate

Deposit Type	Cut-off Grade CuEq%	Short Tons	Metric Tonnes	Cu %	Ni %	Co %	Pt (g/tonne)	Pd (g/tonne)	Au (g/tonne)	Ag (g/tonne)	CuEq %	NiEq %
Indicated
Contact	1.75% CuEq	17,820,000	16,171,000	0.88	1.00	0.03	0.93	1.09	0.36	1.02	2.96	1.88
Footwall	1.75% CuEq	604,000	548,000	0.74	0.41	0.01	3.18	2.59	1.38	4.25	3.62	2.31
Total Indicated	1.75% CuEq	18,424,000	16,719,000	0.87	0.99	0.03	1.00	1.14	0.40	1.12	2.98	1.90
Inferred
Contact Inferred	1.75% CuEq	884,000	802,000	0.59	0.70	0.03	1.03	1.74	0.33	0.29	2.33	1.48

Crean Hill Mineral Resource Estimate Notes:

The effective date of the Crean Hill Property Mineral Resource Estimate (MRE) is April 15, 2026. This is the close out date mine out models (as-builts).
Allan Armitage, Ph.D., P. Geo. of SGS Geological Services is an independent Qualified Person as defined by NI 43-101 101 and is responsible for the current Crean Hill MRE. Armitage conducted multiple site visits to the Crean Hill Property including on May 25-26, 2022, July 25, 2023, July 02, 2024, July 25, 2024 and November 14, 2025.
The classification of the current MRE into Indicated and Inferred mineral resources is consistent with current 2014 CIM Definition Standards – For Mineral Resources and Mineral Reserves.
All figures are rounded to reflect the relative accuracy of the estimate and numbers may not add due to rounding.
The Crean Hill Mineral Resources are inclusive of those Mineral Resources which have been converted to Mineral Reserves.
The mineral resource is presented undiluted and in situ, constrained by 3D grade control resource models, and are considered to have reasonable prospects for eventual economic extraction. The mineral resource is exclusive of mined out material.
Mineral resources which are not mineral reserves do not have demonstrated economic viability. An Inferred Mineral Resource has a lower level of confidence than that applying to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that most Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration.
The Crean Hill mineral resource estimate is based on a validated drill hole database which includes data from 3,892 surface and underground diamond drill holes completed between 1951 and March 2024 and totals 475,773 metres. The resource database totals 98,757 assay intervals, representing 197,536 metres of data.
The mineral resource estimate is based on a three-dimensional (“3D”) resource model of the main mineralization and a broader dilution envelope. 3D models of mined out areas were used to exclude mined out material from the current MRE.
Grades for Ni, Cu, Co, Pt, Pd, Ag and Au are estimated for each mineralization domain using ~2.0 m capped composites assigned to that domain. To generate grade within the blocks, the inverse distance squared (ID2) interpolation method was used for all domains.
Specific gravity values were assigned to each block based on a regression formula defined by a database of 32,592 samples. SG=(0.2057xNi%+2.88).
Based on the size, shape, and orientation of the Crean Hill Deposit, it is envisioned that the deposits may be mined using both bulk and selective mining methods including Longhole Stoping and Mechanized Cut and Fill (MCAF) (mining methods that have long been utilized in the Sudbury region). The MRE is reported at a base case cut-off grade of 1.75% CuEq. The mineral resource grade blocks are quantified above the base case cut-off grade and within the constraining mineralized wireframes (considered mineable shapes).
The underground base case cut-off grade of 1.75% CuEq considers metal prices of $7.30/lb Ni, $4.65/lb Cu, $14.85/lb Co, $1,225/oz Pt, $1,135/oz Pd and $3100/oz Au, metal recoveries of 85% for Ni, 91% for Cu,68% for Co,64% for Pt, 69.5% for Pd and70.5% for Au.
The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.


Table 7: Crean Hill Mineral Reserve Estimate

Deposit Type	Short Tons	Metric Tonnes	Cu %	Ni %	Co %	Pt (g/tonne)	Pd (g/tonne)	Au (g/tonne)	Ag (g/tonne)
Probable
Contact	10,935,000	9,920,065	0.62	0.68	0.02	0.92	1.08	0.38	1.00
Footwall	423,861	384,520	0.55	0.31	0.01	2.35	2.15	1.04	3.20
Total Probable	11,358,861	10,304,585	0.62	0.67	0.02	0.97	1.12	0.40	1.08

Crean Hill Mineral Reserve Estimate Notes:

The effective date of the Crean Hill Mineral Reserve estimate is September 30, 2026.

Mineral Reserves are included within the estimated Mineral Resources.
The Mineral Reserve estimate was prepared under the supervision of Mr. Henri Gouin, P.Eng., of SGS Geological Services and Mr. William van Breugel, P.Eng., Associate Engineer of SGS Geological Services, both considered Qualified Persons as defined by NI 43-101.
Mineral Reserves are based on metal prices of US$4.65/lb Cu, US$7.30/lb Ni, US$14.85/lb Co, US$1225/oz Pt, US$1135/oz Pd, US$3100/oz Au, US$39/oz Ag. Metal recoveries considered are 91% for Cu, 85% for Ni, 68% for Co, 64% for Pt, 69.5% for Pd, 70.5% for Au and 70.5% for Ag.
The estimate of Mineral Reserves may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. The Mineral Reserve Estimate is not a guarantee of economic viability.
A mine design cut-off grade of 1.5% NiEq in-situ was applied to each stope which, after considering recovery and payability, exceeds the estimated costs of sustaining development, equipment and fixed plant capital costs, and operating costs. An incremental stope optimization was subsequently completed using a cut-off grade of 1.2% NiEq.
Stope tons and grades include dilution consisting of 20% and mining losses of 8%.
Figures may not sum exactly due to rounding.

Construction Decision

Based on the results of the PFS prepared in accordance with NI 43-101 Standards of Disclosure for Mineral Projects, authored by independent and experienced Qualified Persons, the Company’s Board of Directors has approved the construction of the Crean Hill Mine. Preliminary work will commence immediately with surface site preparation, detailed engineering, procurement of long lead time items and recruitment of required personnel. The formal start of construction is expected in the first half of 2027.

An exploration diamond drill rig has been mobilized to the Crean Hill Project and has started drill testing new targets for additional footwall copper and precious metals-rich mineralization. Additional assay results will be released in due course.

Third Quarter Results

Magna will release financial and operating results for the third quarter of 2026 after market close on Wednesday November 11, 2026. In addition, the Company will hold a conference call and webcast to discuss these results on Thursday November 12, 2026 at 8:00am ET.

To register for the conference call, please use the following link to obtain a Dial-in Number and PIN: https://register-conf.media-server.com/register/BI977e3342f4ac4bc7af8ea4829f6d91a0

To attend the webcast in listen-only mode, please use the following link: https://edge.media-server.com/mmc/p/6yc2zx2c

Technical Report Filing

The technical report in support of the above noted PFS will be filed by Magna Mining within 45 days of this news release.

Qualified Persons

The following Qualified Persons (QPs) oversaw the completion of the work in preparation of the PFS and are responsible for the contents:

Independent QP for Geology and Mineral Resource Estimates
Mr. Allan Armitage, Ph.D., P.Geo., of SGS Geological Services.
Mr. Armitage conducted a personal inspection of the site on May 25-26, 2022, July 25, 2023, July 02, 2024, July 25, 2024, and November 14, 2025.

Independent QP for Underground Mining and Financial Analysis
Mr. Henri Gouin, P.Eng., of SGS Geological Services.
Mr. Gouin conducted a personal inspection of the site on May 13, 2024 and November 14, 2025.

Independent QP for Underground Mining, Financial Analysis, Permitting and Environmental
Mr. William van Breugel, P.Eng., Associate Engineer of SGS Geological Services.

Independent QP for Processing and Recovery
Mr. David Middleditch, B.Eng., MIMMM, President and Principal Metallurgist of Libertas Metallurgy Limited.

The scientific and technical information in this press release has been reviewed and approved by David King, M.Sc., P.Geo., and Jeff Dawson, P.Eng. Mr. King is the Senior Vice President, Exploration and Geoscience for Magna Mining Inc. and is a qualified person under National Instrument 43-101. Mr. Dawson is the Director, Technical Services for Magna Mining Inc. and is a qualified person under National Instrument 43-101.

Cautionary Statement on Forward-Looking Statements

All statements, other than statements of historical fact, contained or incorporated by reference in this press release constitute “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology, such as “may”, “might”, “potential”, “expect”, “anticipate”, “estimate”, “believe”, “could”, “should”, “would”, “will”, “continue”, “intend”, “plan”, “target”, “forecast”, “prospective”, “significant”, “robust”, “rapid” or other similar words or phrases or variations thereof. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management at the time forward-looking statements are made, are inherently subject to business, market, economic, technical and other risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements, including risks and uncertainties relating to the failure of additional drilling and assays to support assumptions, expectations or estimates of potential mineralization, metal tonnes or grade, the failure of additional drilling to support additional expansion or delineation of estimated resources or reserves, the failure to have accurately estimated declared mineral resources or mineral reserves, the failure of additional drilling to support production planning or replenish production, the failure to maintain an adequate rate of development or access to stopes to maintain production, the failure to realize expected or anticipated production rates, mine life, operating and capital costs, recoveries, processing methods, economic returns, cash flows, net present value, internal rate of return, payback period, government funding or tax incentives, commodity prices, exchange rates, future production, development and operating plans or expansions, permitting and project schedules or timelines, changes in project design, scope or development plans, delays in or the failure to obtain required permits, approvals or authorizations, environmental and regulatory risks, infrastructure and power supply risks, labour, equipment and supply-chain constraints, operational, geotechnical, metallurgical, engineering and construction risks, adverse weather, the lack of availability of drill rigs to implement exploration or other programs or the failure to proceed as quickly as planned with additional exploration, development, production or other drilling, continued delays for assay results, the failure to bring the Crean Hill mine back into commercial production subsequent to the completion of the PFS because of funding or technical issues, and other risks disclosed in the Company’s most recent annual information form for the year ended December 31, 2025, available on the SEDAR+ website (at: www.sedarplus.ca). The PFS is based on a number of assumptions and estimates that are subject to significant uncertainties and contingencies. There is no assurance that the anticipated economic results of the PFS will be realized or that commercial production at the past-producing Crean Hill mine will ever be achieved. A PFS is not a guarantee of economic viability and the results of the PFS may be materially affected by subsequent studies, changes in assumptions, project design, market conditions and other factors. Mineral resources that are not mineral reserves do not have demonstrated economic viability and, particularly, inferred mineral resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. Although the Company has attempted to identify important risks, uncertainties, contingencies and factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, there can be no certainty or assurance that the Company has accurately or adequately captured, accounted for or disclosed all such risks, uncertainties, contingencies or factors. Readers should place no reliance on forward-looking statements as actual results, performance or achievements may be materially different from those expressed or implied by such statements. Resource exploration and development, and mining operations, are highly speculative, characterized by several significant risks, which even a combination of careful evaluation, experience and knowledge will not eliminate. Forward-looking statements speak only as of the date they are made. The Company does not undertake to update any forward-looking statements, whether as a result of new information or future events or otherwise, except in accordance with applicable securities laws.

About Magna Mining Inc.

Magna Mining Inc. is a producing mining company with a strong portfolio of copper, nickel, and precious metals assets located in the world-class Sudbury mining district of Ontario, Canada. The Company’s McCreedy West Mine is currently in production, the adjacent Levack Mine is being restarted, and construction of the Crean Hill Project has been approved. These operations are supported by a pipeline of highly prospective past-producing properties including Podolsky, Kirkwood and Shakespeare.

Magna Mining is strategically positioned to unlock long-term shareholder value through continued production, exploration upside, and near-term development opportunities across its asset base.

Additional corporate and project information is available at www.magnamining.com and through the Company’s public filings on the SEDAR+ website at www.sedarplus.ca.

For further information, please contact:

Jason Jessup
Chief Executive Officer

Paul Fowler, CFA
Executive Vice President
705-482-9667
Email: info@magnamining.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/b9171140-a48f-49d2-bd96-021c9e03e979

https://www.globenewswire.com/NewsRoom/AttachmentNg/2492931b-244d-4fd7-ac6d-3ee5409c6391

https://www.globenewswire.com/NewsRoom/AttachmentNg/c26f02ce-c440-497c-a30e-736e86b702cf

https://www.globenewswire.com/NewsRoom/AttachmentNg/7b666503-e01e-4a1c-a145-1fe2ba21a558

https://www.globenewswire.com/NewsRoom/AttachmentNg/708632c8-6110-4e75-9315-5a3775073f58

https://www.globenewswire.com/NewsRoom/AttachmentNg/ac9ec28e-a3bc-4a1a-85a4-6c2f807242ee

Posted in UncategorizedTagged GlobeNewswire

Form 8.5 (EPT/RI)-Logistics Development Group plc

Posted on October 21, 2026 by Ravi Shankar

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:	Investec Bank Plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	Logistics Development Group plc
(c) Name of the party to the offer with which exempt principal trader is connected:	Investec is Financial Adviser to DBAY Advisors Limited
(d) Date dealing undertaken:	20^th October 2026
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A”	N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	62,000	23	23
Ordinary shares	Sales	70,525	23.1	23

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii) Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	21^st October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Posted in UncategorizedTagged GlobeNewswire

Summary Results of Operations (Unaudited)

	Three Months Ended								Nine Months Ended
(000s, except per share amounts)	9/30/2026		9/30/2025		% Change	6/30/2026		% Change	9/30/2026		9/30/2025		% Change
Revenues:
Commissions	$200,756		$206,075		(2.6)	$221,462		(9.3)	$630,052		$600,414		4.9
Principal transactions		117,124		177,876	(34.2)		140,091	(16.4)		407,436		492,139	(17.2)
Investment banking		306,203		323,483	(5.3)		331,954	(7.8)		979,569		794,885	23.2
Asset management		492,163		431,399	14.1		456,630	7.8		1,408,250		1,244,548	13.2
Other income		8,299		14,228	(41.7)		12,549	(33.9)		76,527		28,499	168.5
Operating revenues		1,124,545		1,153,061	(2.5)		1,162,686	(3.3)		3,501,834		3,160,485	10.8
Interest revenue		510,624		481,504	6.0		476,093	7.3		1,437,766		1,434,192	0.2
Total revenues		1,635,169		1,634,565	0.0		1,638,779	(0.2)		4,939,600		4,594,677	7.5
Interest expense		208,958		205,169	1.8		187,975	11.2		584,424		625,526	(6.6)
Net revenues		1,426,211		1,429,396	(0.2)		1,450,804	(1.7)		4,355,176		3,969,151	9.7
Non-interest expenses:
Compensation and benefits		813,494		839,820	(3.1)		833,018	(2.3)		2,494,846		2,346,976	6.3
Non-compensation operating expenses		303,092		303,530	(0.1)		318,348	(4.8)		925,195		1,058,945	(12.6)
Total non-interest expenses		1,116,586		1,143,350	(2.3)		1,151,366	(3.0)		3,420,041		3,405,921	0.4
Income before income taxes		309,625		286,046	8.2		299,438	3.4		935,135		563,230	66.0
Provision for income taxes		75,482		74,675	1.1		72,961	3.5		223,096		143,812	55.1
Net income		234,143		211,371	10.8		226,477	3.4		712,039		419,418	69.8
Preferred dividends		9,320		9,320	0.0		9,321	(0.0)		27,961		27,961	0.0
Net income available to common shareholders	$224,823		$202,051		11.3	$217,156		3.5	$684,078		$391,457		74.8
Earnings per common share:⁽¹⁾
Basic	$1.48		$1.31		13.0	$1.41		5.0	$4.45		$2.52		76.6
Diluted	$1.40		$1.22		14.8	$1.34		4.5	$4.23		$2.37		78.5
Cash dividends declared per common share⁽¹⁾	$0.34		$0.31		9.7	$0.34		0.0	$1.02		$0.93		9.7
Weighted average number of common shares outstanding:⁽¹⁾
Basic		151,956		154,679	(1.8)		154,234	(1.5)		153,889		155,603	(1.1)
Diluted		160,145		165,087	(3.0)		161,631	(0.9)		161,744		164,877	(1.9)

Non-GAAP Financial Measures ⁽¹¹⁾

	Three Months Ended						Nine Months Ended
(000s, except per share amounts)	9/30/2026			9/30/2025			9/30/2026			9/30/2025
GAAP net income		234,143		$	211,371			712,039		$	419,418
Preferred dividend		9,320			9,320			27,961			27,961
Net income available to common shareholders		224,823			202,051			684,078			391,457

Non-GAAP adjustments:
Net revenue adjustments ^{(12) (13)}		2,866			2			(31,273	)		80
Merger-related ⁽¹⁴⁾		8,219			12,676			50,090			45,635
Restructuring and severance ⁽¹⁵⁾		1,174			4,065			3,504			31,106
Provision for income taxes ⁽¹⁶⁾		(2,986	)		(4,375	)		(5,527	)		(13,997	)
Total non-GAAP adjustments		9,273			12,368			16,794			62,824
Non-GAAP net income available to common shareholders	$	234,096		$	214,419		$	700,872		$	454,281

Weighted average diluted shares outstanding ⁽¹⁾		160,145			165,087			161,744			164,877

GAAP earnings per diluted common share ⁽¹⁾	$	1.46		$	1.28		$	4.41		$	2.53
Non-GAAP adjustments ⁽¹⁾		0.06			0.08			0.10			0.39
Non-GAAP earnings per diluted common share ⁽¹⁾	$	1.52		$	1.36		$	4.51		$	2.92

GAAP earnings per diluted common share available to common shareholders ⁽¹⁾	$	1.40		$	1.22		$	4.23		$	2.37
Non-GAAP adjustments ⁽¹⁾		0.06			0.08			0.10			0.39
Non-GAAP earnings per diluted common share available to common shareholders ⁽¹⁾	$	1.46		$	1.30		$	4.33		$	2.76

GAAP to Non-GAAP Reconciliation ⁽¹¹⁾

	Three Months Ended						Nine Months Ended
(000s)	9/30/2026			9/30/2025			9/30/2026			9/30/2025
GAAP net revenues	$1,426,211			$1,429,396			$4,355,176			$3,969,151
Non-GAAP adjustments:
Gain on sale of business ⁽¹²⁾		2,866			—			(44,418	)		—
Litigation-related and other ⁽¹³⁾		—			2			13,145			80
Total non-GAAP adjustments		2,866			2			(31,273	)		80
Non-GAAP net revenues	$1,429,077			$1,429,398			$4,323,903			$3,969,231

GAAP compensation and benefits	$813,494			$839,820			$2,494,846			$2,346,976
As a percentage of net revenues		57.0%			58.8%			57.3%			59.1%
Non-GAAP adjustments:
Merger-related ⁽¹⁴⁾		(3,463	)		(6,704	)		(25,226	)		(13,706	)
Restructuring and severance ⁽¹⁵⁾		(1,174	)		(4,065	)		(3,504	)		(31,106	)
Total non-GAAP adjustments		(4,637	)		(10,769	)		(28,730	)		(44,812	)
Non-GAAP compensation and benefits	$808,857			$829,051			$2,466,116			$2,302,164
As a percentage of non-GAAP net revenues		56.6%			58.0%			57.0%			58.0%

GAAP non-compensation expenses	$303,092			$303,530			$925,195			$1,058,945
As a percentage of net revenues		21.3%			21.2%			21.2%			26.7%
Non-GAAP adjustments:
Merger-related ⁽¹⁴⁾		(4,756	)		(5,972	)		(24,864	)		(31,929	)
Non-GAAP non-compensation expenses	$298,336			$297,558			$900,331			$1,027,016
As a percentage of non-GAAP net revenues		20.9%			20.8%			20.9%			25.9%
Total adjustments before income taxes	$12,259			$16,743			$22,321			$76,821

Footnotes

⁽¹⁾	All share and per share information has been retroactively adjusted to reflect the February 2026 three-for-two stock split.
⁽²⁾	Represents available to common shareholders.
⁽³⁾	Reconciliations of the Company’s GAAP results to these non-GAAP measures are discussed within and under “Non-GAAP Financial Measures” and “GAAP to Non-GAAP Reconciliation.”
⁽⁴⁾	Non-GAAP pre-tax margin is calculated by adding total merger-related expenses (non-GAAP adjustments) and dividing it by non-GAAP net revenues. See “Non-GAAP Financial Measures” and “GAAP to Non-GAAP Reconciliation.”
⁽⁵⁾	Return on average common equity (“ROCE”), a non-GAAP financial measure, is calculated by dividing full year or annualized net income applicable to common shareholders by average common shareholders’ equity.
⁽⁶⁾	Return on average tangible common equity (“ROTCE”), a non-GAAP financial measure, is calculated by dividing full year or annualized net income applicable to common shareholders by average tangible common equity. Tangible common equity, also a non-GAAP financial measure, equals total common shareholders’ equity less goodwill and identifiable intangible assets and the deferred taxes on goodwill and intangible assets. Average deferred taxes on goodwill and intangible assets were $95.0 million and $87.2 million as of September 30, 2026, and 2025, respectively.
⁽⁷⁾	Total client assets and fee-based client assets as of September 30, 2025, include $10.2 billion and $4.8 billion, respectively, of client assets from the Stifel Independent Advisors business that was sold on February 2, 2026.
⁽⁸⁾	Includes loans held for sale.
⁽⁹⁾	Tangible book value per common share, a non-GAAP financial measure, represents shareholders’ equity (excluding preferred stock) divided by period end common shares outstanding. Tangible common shareholders’ equity equals total common shareholders’ equity less goodwill and identifiable intangible assets and the deferred taxes on goodwill and intangible assets.
⁽¹⁰⁾	Capital ratios are estimates at the time of the Company’s earnings release, October 21, 2026.
⁽¹¹⁾	The Company prepares its Consolidated Financial Statements using accounting principles generally accepted in the United States (U.S. GAAP). The Company may disclose certain “non-GAAP financial measures” during its earnings releases, earnings conference calls, financial presentations and otherwise. The Securities and Exchange Commission defines a “non-GAAP financial measure” as a numerical measure of historical or future financial performance, financial position, or cash flows that is subject to adjustments that effectively exclude, or include, amounts from the most directly comparable measure calculated and presented in accordance with U.S. GAAP. Non-GAAP financial measures disclosed by the Company are provided as additional information to analysts, investors and other stakeholders in order to provide them with greater transparency about, or an alternative method for assessing the Company’s financial condition or operating results. These measures are not in accordance with, or a substitute for U.S. GAAP, and may be different from or inconsistent with non-GAAP financial measures used by other companies. Whenever the Company refers to a non-GAAP financial measure, it will also define it or present the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, along with a reconciliation of the differences between the non-GAAP financial measure it references and such comparable U.S. GAAP financial measure.
⁽¹²⁾	Gain recognized on the sale of Stifel Independent Advisors, LLC during the first quarter of 2026.
⁽¹³⁾	Primarily related to prejudgment interest recognized on legal matters.
⁽¹⁴⁾	Primarily related to charges attributable to integration-related activities, signing bonuses, amortization of restricted stock awards, debentures, and promissory notes issued as retention, additional earn-out expense, and amortization of intangible assets acquired. These costs were directly related to acquisitions of certain businesses and are not representative of the costs of running the Company’s on-going business.
⁽¹⁵⁾	The Company recorded severance costs associated with workforce reductions in certain of its foreign subsidiaries.
⁽¹⁶⁾	Primarily represents the Company’s effective tax rate for the period applied to the non-GAAP adjustments.